GLPG — Galapagos N.V.

Summary of Galapagos (GLPG) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Net Revenues: EUR 6.5 million, a significant decrease from EUR 75 million in Q1 2025, primarily due to the prior year’s revenue recognition from the OLCA.
• Revenue Breakdown: EUR 4.9 million from Jyseleca inventory sales and EUR 1.6 million in collaboration revenues from Gilead.
• Operating Expenses: R&D expenses decreased to EUR 31 million, contributing to an improved operating loss of EUR 63.7 million compared to EUR 158.7 million in the previous year.
• Net Financial Income: EUR 77.7 million, largely due to favorable currency exchange gains, resulting in a net profit of EUR 14.5 million compared to a net loss of EUR 153.4 million in Q1 2025.
• Cash Position: Cash and cash equivalents totaled EUR 2.98 billion as of March 31, 2026, down from EUR 3.3 billion a year prior, benefiting from favorable exchange rates.

2. Strategic Updates and Business Highlights

• Name Change: The company is rebranding to Lakefront Biotherapeutics, reflecting its transformation and strategic focus.
• Management and Board Changes: A new management team and Board Chair, Gino Santini, have been appointed to guide the company through its new phase.
• Partnership with Gilead: A binding agreement was reached regarding Ouro Medicines, focusing on the lead program gamgertamig, a promising T cell engager for autoimmune diseases, with potential for significant revenue.
• Pipeline Expansion: The collaboration includes three preclinical programs, with gamgertamig expected to enter registrational studies by 2027.

3. Forward Guidance and Outlook

• Ouro Transaction Costs: Expected cash expenditures related to the Ouro transaction are projected between EUR 775 million and EUR 790 million for 2026.
• Cash Guidance: The company anticipates ending 2026 with EUR 1.975 billion to EUR 2.05 billion in cash and equivalents, maintaining a strong financial position for future strategic initiatives.

4. Challenges and Points of Concern

• Revenue Decline: The significant drop in revenues compared to the previous year raises concerns about the sustainability of income streams.
• Operational Losses: Although improved, the operating loss remains substantial, indicating ongoing financial pressures.
• Market Competition: The BCMA/CD3 T cell engager space is becoming crowded, raising questions about the competitive positioning of gamgertamig amidst other emerging therapies.

5. Notable Q&A Insights

• Clinical Data Requirements: Management discussed the need for gamgertamig to demonstrate profound B-cell depletion and minimal cytokine release syndrome (CRS) to advance into registrational trials, with expectations for data releases in upcoming months.
• Indication Selection: The company is prioritizing indications where they can achieve rapid clinical signals and where current treatments are inadequate, suggesting a strategic focus on smaller, manageable patient populations.
• BD Activities: There is a cautious approach to future business development, with a high bar set for new deals following the successful Ouro transaction, emphasizing the strength of the current portfolio.
• Infection Risks: Discussions highlighted the importance of managing infection risks associated with B-cell depletion, with ongoing assessments to optimize dosing schedules.

This summary encapsulates the key financial metrics, strategic initiatives, and insights from the Q&A, providing a balanced view of Galapagos's current position and future outlook.